November 24, 2025 Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP Biodexa Pharmaceuticals PLC (Nasdaq:…
PHILADELPHIA, Nov. 24, 2025 (GLOBE NEWSWIRE) -- November is Men’s Health Awareness Month, a time to spotlight the latest medical…
Proceeds will fully retire debt facility from OrbiMed and fund company operations, thereby extending expected cash runway into mid-2027Financing anchored…
Updated data expands clinically meaningful results available from FIREFLY-1 pivotal trial 77% of patients who entered the treatment-free observation period…
CHARLOTTE, N.C., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), the parent company…
Record-setting presence at ASH reflects widespread recognition of clonoSEQ as a standard-of-care tool for personalizing patient care and accelerating drug…
HOUSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a healthcare company developing and commercializing precision…
Montreal, Quebec--(Newsfile Corp. - November 21, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"),…
Leading edge artificial intelligence and machine learning platform supports enhanced salesforce targeting and engagement for cutaneous T-cell lymphoma immunotherapy launchCRANFORD,…
IRVING, Texas, Nov. 21, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision…